Sobolenko V
Centre for Addiction and Mental Health, University of Toronto, Toronto, ON, Canada.
ArticlePsilocybin
Microdosing psychedelics: What, why, when, and how often? Insights from an international survey of people who use psychedelics.
ArticleKetamine
Clinical Predictors of Antidepressant Effects of Ketamine and Esketamine in Treatment-Resistant Unipolar and Bipolar Depression: A Systematic Review.
ArticlePsilocybin
Microdosing psilocybin for major depressive disorder: study protocol for a phase II double-blind placebo-controlled randomised partial crossover trial - CORRIGENDUM.
ArticlePsilocybin
Microdosing psilocybin for major depressive disorder: study protocol for a phase II double-blind placebo-controlled randomised partial crossover trial.
PreprintPsilocybin
Microdosing Psilocybin for Major Depressive Disorder: Study Protocol for a Phase II Double-Blind Placebo-Controlled Randomized Partial Crossover Trial
ArticlePsilocybin
Preferences, Perceptions, and Environmental Considerations of Natural and Synthetic Psychedelic Substances: Findings from the Global Psychedelic Survey.
ArticlePsilocybin